Related Experiment Video

Updated: Jul 30, 2025

Assessment of the Metabolic Effects of Isocaloric 2:1 Intermittent Fasting in Mice
08:06

Assessment of the Metabolic Effects of Isocaloric 2:1 Intermittent Fasting in Mice

Published on: November 27, 2019

9.0K

Efficacy and safety of modified fasting therapy for weight loss in 2054 hospitalized patients

Taoli Liu1, Ziheng Ye1, Jiahao Feng2

  • 1Traditional Chinese Medicine Department, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, China.

Obesity (Silver Spring, Md.)
|May 19, 2023
PubMed
Abstract

Insights

Modified fasting therapy for 7 days effectively and safely improved health indicators in 2054 patients. This intervention reduced weight, blood pressure, and improved body composition, benefiting cardiovascular health.

Area of Science:

  • Clinical Medicine
  • Nutritional Science
  • Metabolic Health

Background:

  • Modified fasting therapy is increasingly explored for health benefits.
  • Understanding its impact on clinical indicators and body composition is crucial.

Purpose of the Study:

  • To evaluate the efficacy and safety of a 7-day modified fasting therapy.
  • To analyze changes in clinical indicators and body composition in hospitalized patients.

Main Methods:

  • Retrospective observational study of 2054 hospitalized patients.
  • Participants underwent 7 days of modified fasting therapy.
  • Clinical efficacy biomarkers, safety indicators, and body composition were measured pre- and post-fasting.

Main Results:

  • Significant reductions observed in body weight, BMI, abdominal circumference, systolic, and diastolic blood pressure.
  • Improvements noted in blood glucose and body composition indicators (p < 0.05).
  • Minor increases in liver function, kidney function, uric acid, electrolytes, blood count, coagulation, and uric biomarkers.

Conclusions:

  • The 7-day modified fasting therapy is effective and safe in a large patient population.
  • The therapy improves physical health, body weight-associated indicators, and body composition.
  • Benefits extend to cardiovascular risk factors, with positive outcomes in cardiovascular disease patients.

More Related Videos

A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood11:36

A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood

Published on: April 28, 2016

9.4K
Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes08:30

Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes

Published on: March 15, 2018

14.2K

Related Concept Videos

Metabolic States of the Body: Fasting and Starvation01:24

Metabolic States of the Body: Fasting and Starvation

During the initial hours of fasting, the body uses up its glycogen stores as an energy source. Once these glycogen reserves are depleted, the body begins breaking down stored triglycerides and structural proteins. During this stage, glycerol becomes a key substrate for gluconeogenesis, while free fatty acids undergo beta-oxidation to provide energy for tissues, such as skeletal muscle. In the fasting state, the body spares protein breakdown as much as possible to conserve muscle and structural...
1.6K
Metabolic States of the Body: The Postabsorptive State01:18

Metabolic States of the Body: The Postabsorptive State

The postabsorptive state usually starts about four hours after a meal and lasts until the next meal is eaten. During this time, the digestive system stops absorbing nutrients, and the body uses stored energy reserves to maintain stable blood glucose levels.
Initially, glycogen stored in the liver is broken down to release glucose into the bloodstream, while glycogen in the muscles is broken down to supply glucose for energy directly within the muscle cells. As glycogen stores diminish,...
395
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
306
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
18
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
217
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
319